Partner Headlines - BMY

  1. Screening Pharma Stocks Amid Turnaround

    YCharts
  2. Incyte Building Blockbuster Drug One Disease At A Time

    IBD
  3. Blackhill Bets Almost Half of Portfolio on Williams-Sonoma

    GuruFocus
  4. Merck Down On Hepatitis C Data; Gilead Rises

    IBD
  5. A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio

    GuruFocus
  6. Dan Nathan Sees Unusual Options Activity In Bristol-Myers Squibb ...

    Benzinga
  7. Lung cancer drug promising

    IBD
  8. Bristol-Myers Lung-Cancer Drug Boosts Survival

    IBD
  9. #PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line ...

    Benzinga
  10. Eliquis revives Bristol-Myers

    IBD
  11. Bristol-Myers Beats Q3 Views As Eliquis Revives

    IBD
  12. Stocks Flat In Mixed Volume; Amazon.com Weighs On Techs

    IBD
  13. UPDATE: Bristol-Myers Squibb Q3 Earnings Top Estimates

    Benzinga
  14. Stock Futures Aim For Flat Open; Amazon.com Crumples On Q3 Miss

    IBD
  15. #PreMarket Primer: Friday, October 24: Ebola Fears Weigh On Markets

    Benzinga
  16. Earnings Scheduled For October 24, 2014

    Benzinga
  17. Must Watch Stocks for Today

    Benzinga
  18. Stocks Rebound; Amazon.com Slides After Hours

    IBD
  19. Drug ETFs Attractive Buys On Pullback

    Benzinga
  20. Weekly CFO Sells Highlight: Williams Companies Inc, Google Inc, ...

    GuruFocus
  21. Benzinga Weekly Preview: Earnings Season Is In Full Swing

    Benzinga
  22. Apple Leads the Charge as Earnings Season Heats Up

    FoxBusiness
  23. The Six Types of Winning Stocks

    GuruFocus
  24. Markets Debut Week On Negative Note; S&P 500 Falls Through Key ...

    Benzinga
  25. Merck to release hep C data

    IBD
  26. Merck, Bristol, Arrowhead Prep Hepatitis Studies

    IBD
  27. Salix, Actavis Among Big Cap Pharmas In Merger Mambo

    IBD
  28. Bristol-Myers pulls FDA filing

    IBD
  29. Bristol-Myers Pulls FDA Filing For 2-Drug Hep C Combo

    IBD
  30. Bristol-Myers Squibb Statement About Asunaprevir In The US, WIthdraws ...

    Benzinga
  31. 2 Mutual Funds Holding Hospital Stocks

    Benzinga
  32. NeurOp Receives Milestone Payment As Bristol-Myers Squibb Nominates ...

    Benzinga
  33. Morgan Stanley Believes Bristol-Myers Squibb Co. Could Move Significantly ...

    Benzinga
  34. Gilead's New HIV Drug Key To Long-Term Strategy

    IBD
  35. Gilead OKs Generic Sovaldi To Expand Global Access

    IBD
  36. Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. ...

    Benzinga
  37. Merck PD-1 Inhibitor Approved For Skin Cancer

    IBD
  38. Drug M&A Boom Driven By Long-Term Trends: PwC

    IBD
  39. Booming Biotech Market Benefits REIT BioMed Realty

    IBD
  40. Bristol-Myers: Absolute Valuation Model versus Relative Valuation ...

    GuruFocus
  41. Bristol-Myers Drug Gets OK

    IBD
  42. Markets Little Changed In Low Volume And Slow News Ahead Of Long ...

    Benzinga
  43. Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers ...

    Benzinga
  44. Bristol-Myers Hepatitis C Therapy Approved in EU

    IBD
  45. US Stock Futures Edge Higher Ahead Of Tiffany Earnings

    Benzinga
  46. Merck, Pfizer Combining Drugs In Lung Cancer Study

    IBD
  47. Intercept Pharma Soars On Liver-Disease Drug Data

    IBD
  48. Markets Marginally Higher On Light Volume And Encouraging Geopolitical ...

    Benzinga
  49. Drugmaker AstraZeneca Returns To Growth

    IBD
  50. The Stocks Already in Correction Mode

    FoxBusiness
  51. Will ImmunoGen's Q4 Earnings Disappoint Again?

    GuruFocus
  52. Bristol-Myers surprises Street

    IBD
  53. Thursday Morning Earnings Reports

    Benzinga
  54. Stock Futures Steer Higher; Facebook, Skechers Nail Q2 Wins

    IBD
  55. Earnings Scheduled For July 24, 2014

    Benzinga
  56. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  57. Benzinga Weekly Preview: Earnings Season Continues With Geopolitical ...

    Benzinga
  58. UnitedHealth Group Up on Weak Day for the Dow

    GuruFocus
  59. Dow Sets New Intraday High; Citigroup Impresses With Earnings

    Benzinga
  60. Senators Ask Gilead To Explain Sovaldi Pricing

    IBD
  61. Bristol seeks cancer drug nod

    IBD
  62. Bristol-Myers Seeking Nivolumab Approval In Melanoma

    IBD
  63. Japan approves BMY regimen

    IBD
  64. Jazz, Novo Among Medicals Showing Healthy Action

    IBD
  65. Bristol-Myers' All-Oral HCV Therapy Approved In Japan

    IBD
  66. Merck, Gilead Lead Race To Eradicate Hepatitis C

    IBD
  67. Markets Little Changed Ahead Of 4th Of July Break

    Benzinga
  68. Barclays Downgrades Pharmaceutical Sector

    Benzinga
  69. UPDATE: Barclays Downgrades Bristol-Myers, Cuts Price Target ...

    Benzinga
  70. Benzinga's Top Downgrades

    Benzinga
  71. Ex-Dividends For July 1, 2014

    Benzinga
  72. Pfizer and others get EU nods

    IBD
  73. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  74. Pfizer, Bristol-Myers Squibb Announce Positive Opinion For Treatments

    Benzinga
  75. US Stock Futures Drop Ahead Of Consumer Sentiment Report

    Benzinga
  76. Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza ...

    Benzinga
  77. Pharma Sector Stocks To Consider For Sustained Returns

    GuruFocus
  78. Bristol-Myers Stock Up On Nivolumab Trial Success

    IBD
  79. BRISTOL-MYERS SQUIBB

    IBD
  80. UPDATE: Bristol Myers Announces Phase 3 First-Line Study of Nivolumab ...

    Benzinga
  81. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  82. Merck Takes The 'Nuc' Option In Hepatitis C Race

    IBD
  83. ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy

    Benzinga
  84. ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?

    Benzinga
  85. Bristol-Myers Offers Two-, Three-Year Survival Data for Nivolumab

    Benzinga
  86. AstraZeneca Woos Shareholders With Promise Of Growth

    IBD
  87. Vanguard Health Care Fund's Top Quarterly Holdings

    GuruFocus
  88. Bristol, Merck Q1 sales soft

    IBD
  89. Bristol, Merck, Sanofi Report Soft Q1 Sales

    IBD
  90. ETF Outlook For Tuesday, April 29, 2014 (IHE, TAN, XRT, SOCL, ...

    Benzinga
  91. UPDATE: Bristol-Myers Posts Higher Q1 Profit

    Benzinga
  92. US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

    Benzinga
  93. Bristol-Myers Squibb Acquires iPierian for $175M, Potential Milestone ...

    Benzinga
  94. Earnings Scheduled For April 29, 2014

    Benzinga
  95. Stocks To Watch For April 29, 2014

    Benzinga
  96. Pfizer Confirms Pursuit Of AstraZeneca; Stocks Jump

    IBD
  97. Earnings Expectations For The Week Of April 28: Big Oil, Big ...

    Benzinga
  98. Benzinga Weekly Preview: Earnings Season Continues As Biotech ...

    Benzinga
  99. Week Ahead: April Jobs Report, FOMC Meeting and Earnings

    FoxBusiness
  100. Pfizer, AstraZeneca Rise On Report Of Merger Talks

    IBD
Trading Center